![Bertil Lindmark](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 38 015 $ al 31/05/2026
Dr. Bertil E.
Lindmark is a Venture Partner at Xgen Venture Sgr SpA, a Chairman of the Board at Aqilion AB, an Independent Director at ALK-Abello A/S and a Professor-Emeritus at University of Gothenburg.
He is on the Board of Directors at ALK-Abello A/S, Cellevate AB and Aslan Pharmaceuticals (Shanghai) Co. Ltd. Dr. Lindmark was previously employed as a Chief Medical Officer by Vicore Pharma Holding AB, a Chief Medical Officer by Galecto, Inc., a Chief Medical Officer by eTheRNA immunotherapies NV, a Chief Scientific & Medical Officer by ASLAN Pharmaceuticals Pte Ltd., an Executive Director & Executive Director-R&D by Almirall SA, a Head-Clinical Development by AstraZeneca Japan Ltd., and a Vice President by AstraZeneca Pharma India Ltd. He also served on the board at Medicon Valley Alliance FMBA. He received his doctorate degree from the University of Lund.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VICORE PHARMA HOLDING AB 0,01 % | 31/12/2025 | 30.000 ( 0,01 % ) | 38 015 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ALK-ABELLÓ A/S | Director/Miembro de la Junta | 18/03/2021 |
Aslan Pharmaceuticals (Shanghai) Co. Ltd. | Director/Miembro de la Junta | - |
Cellevate AB
 Cellevate AB BiotechnologyHealth Technology Develops cell culture products for gene therapy and provides novel vaccines biomanufacturing services | Director/Miembro de la Junta | 01/02/2019 |
Xgen Venture Sgr SpA
 Xgen Venture Sgr SpA Investment ManagersFinance XGEN Venture invests in companies located in Italy. The firm focuses on the life science sectors. It participates in early stage capital transactions. | Inversor de Capital Privado | 01/01/2023 |
Aqilion AB
 Aqilion AB Investment ManagersFinance Aqilion AB is an active manager which invests companies located in Sweden. The firm follows of life science companies. It provides financing for early-stage capital requirements. | Presidente | 01/08/2022 |
University of Gothenburg
 University of Gothenburg Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Empresas | Cargo | Fin |
|---|---|---|
| VICORE PHARMA HOLDING AB | Director Técnico/Científico/I+D | 05/03/2026 |
| DAMORA THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/10/2023 |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Director Técnico/Científico/I+D | 01/01/2020 |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 15 |
|---|---|
Almirall SA
 Almirall SA Pharmaceuticals: MajorHealth Technology Engages in the development, manufacture and sale of pharmaceuticals | Health Technology |
ALK-Abello A/S
 ALK-Abello A/S Pharmaceuticals: MajorHealth Technology Develops and produces, markets products for diagnosing, treating allergies, allergic asthma & acute anaphylactic reactions | Health Technology |
AstraZeneca Pharma India Ltd.
 AstraZeneca Pharma India Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
University of Lund
 University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Gothenburg
University of Gothenburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aqilion AB
Aqilion AB Investment ManagersFinance Aqilion AB is an active manager which invests companies located in Sweden. The firm follows of life science companies. It provides financing for early-stage capital requirements. | Finance |
Astrazeneca Japan Ltd.
 Astrazeneca Japan Ltd. Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
Medicon Valley Alliance FMBA
 Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Operates Danish-Swedish life science cluster Medicon Valley | Commercial Services |
Vicore Pharma Holding AB
 Vicore Pharma Holding AB Pharmaceuticals: MajorHealth Technology Engages in research and development of drugs for lung diseases | Health Technology |
ASLAN Pharmaceuticals Pte Ltd.
 ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology Develops novel medicines for global markets | Health Technology |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Health Technology |
Aslan Pharmaceuticals (Shanghai) Co. Ltd. | |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
Cellevate AB
Cellevate AB BiotechnologyHealth Technology Develops cell culture products for gene therapy and provides novel vaccines biomanufacturing services | Health Technology |
Xgen Venture Sgr SpA
Xgen Venture Sgr SpA Investment ManagersFinance XGEN Venture invests in companies located in Italy. The firm focuses on the life science sectors. It participates in early stage capital transactions. | Finance |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
